AI Article Synopsis
- Metastatic colorectal cancer (mCRC) is a complex disease, and this review focuses on how molecular characteristics influence treatment options for patients.
- The review discusses various studies that highlight the importance of molecular biomarkers, emphasizing that certain treatments like anti-EGFR drugs are best suited for patients with specific genetic profiles, while others like antiangiogenic therapies and immunotherapy show broad effectiveness.
- The conclusion draws attention to the progress being made in personalized treatment plans for mCRC, but stresses the need for more extensive research and trials to enhance patient care and outcomes.
Article Abstract
Background: Metastatic CRC (mCRC) is a molecular heterogeneous disease. The aim of this review is to give an overview of molecular-driven treatment of mCRC patients.
Methods: A review of clinical trials, retrospective studies and case reports was performed regarding molecular biomarkers with therapeutic implications.
Results: wild-type status was confirmed as being crucial for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and for rechallenge strategy. Antiangiogenic therapies improve survival in first- and second-line settings, irrespective of status, while tyrosine kinase inhibitors (TKIs) remain promising in refractory mCRC. Promising results emerged from anti-HER2 drugs trials in HER2-positive mCRC. Target inhibitors were successful for mutant mCRC patients, while immunotherapy was successful for microsatellite instability-high/defective mismatch repair (MSI-H/dMMR) or DNA polymerase epsilon catalytic subunit () mutant patients. Data are still lacking on , and TGF-β, which require further research.
Conclusion: Several molecular biomarkers have been identified for the tailored treatment of mCRC patients and multiple efforts are currently ongoing to increase the therapeutic options. In the era of precision medicine, molecular-biology-driven treatment is the key to impro patient selection and patient outcomes. Further research and large phase III trials are required to ameliorate the therapeutic management of these patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281737 | PMC |
| http://dx.doi.org/10.3390/cancers12051214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.
Int J Mol Sci
June 2023
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy.
The treatment of chronic lymphocytic leukemia (CLL) currently relies on the use of chemo-immunotherapy, Bruton's tyrosine kinase inhibitors, or BCL2 inhibitors alone or combined with an anti-CD20 monoclonal antibody. However, the availability of multiple choices for the first-line setting and a lack of direct head-to-head comparisons pose a challenge for treatment selection. To overcome these limitations, we performed a systematic review and a network meta-analysis on published randomized clinical trials performed in the first-line treatment setting of CLL.
View Article and Find Full Text PDFMolecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.
Cancers (Basel)
May 2020
Medical Oncology Unit, University Hospital and University of Cagliari, 09042 Cagliari, Italy.
Article Synopsis
- Metastatic colorectal cancer (mCRC) is a complex disease, and this review focuses on how molecular characteristics influence treatment options for patients.
- The review discusses various studies that highlight the importance of molecular biomarkers, emphasizing that certain treatments like anti-EGFR drugs are best suited for patients with specific genetic profiles, while others like antiangiogenic therapies and immunotherapy show broad effectiveness.
- The conclusion draws attention to the progress being made in personalized treatment plans for mCRC, but stresses the need for more extensive research and trials to enhance patient care and outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!